News & Events
CPRIT and Salarius Pharmaceuticals
CPRIT makes childhood cancer a priority with 12% of its portfolio going to childhood cancer research — proportionately 3 times more than the national commitment. Ewing’s Sarcoma is a rare and devastating bone and soft-tissue cancer that mostly afflicts children and young adults for which no approved targeted therapies are currently available.
CPRIT and Hummingbird Bioscience
CPRIT is participating in BIO 2019 this week in Philadelphia with over 16,000 attendees representing the biotech and pharma industry from around the world. We will be educating them on funding opportunities for CPRIT’s Product Development Research program which is currently accepting applications for our Company Relocation Awards, Texas Company Awards, and Seed Awards.
Cancer Prevention & Research Institute of Texas Awards New Grants
AUSTIN — The Cancer Prevention and Research Institute of Texas (CPRIT) today awarded 10 new academic research grants totaling over $31 million to recruit eminent cancer researchers to Texas.
Statement from CPRIT CEO Wayne Roberts on Senate passage of HJR 12
"Twelve years ago, Texas made history with an unprecedented initiative to take on cancer. Texas is clearly showing that the investment and focus have been worth it. We are making enormous progress in advancing the understanding of cancer science, accelerating potential cures and prevention strategies, and transforming the cancer landscape in Texas."
CPRIT Legislative Update
Today, the Texas Senate Committee on Finance unanimously approved HJR 12 by a vote of 10-0. This vote now clears the way for the bill to be considered by the full Senate.
CPRIT Legislative Update
This week, the Texas House of Representatives approved House Joint Resolution (HJR) 12 and House Bill (HB) 39 both by Rep. John Zerwas.
Our Grantees in the News
Media Contact
Mark Loeffler
Communications Director
Phone: 512-305-8483
Email: [email protected]